health
SLR14 shows antiviral effects against five RNA viruses in preclinical tests
A bioRxiv preprint reports that the RIG-I agonist SLR14 reduced infection or viral replication in human-derived cells and improved outcomes in infected mice. The findings come from cell and animal experiments, not human treatment studies.